Dr. Dean Mitchell sits down with Dr. Lawrence Lustig, Howard W. Smith Professor and Chair of Otolaryngology Head and Neck Surgery at Columbia University, to discuss a gene therapy called Otofarmaní that has recently received FDA approval for a rare genetic form of deafness caused by mutations in the otoferlin gene. Dr. Lustig, one of the lead investigators in the clinical trial, explains how the therapy works, why this particular form of deafness made it a viable candidate, and what the results looked like across their first 12 patients.

The conversation covers the decades of foundational science that made this possible, from early genetics research in the 1980s and 90s to the dual-vector delivery technique that solved the problem of the otoferlin gene being too large for a single viral vector. Dr. Lustig walks through how the inner ear functions, why otoferlin-related deafness preserves inner ear structures long enough to allow intervention, and how hearing recovery typically unfolds over weeks to months in treated children. The discussion also addresses the significant variability in outcomes across patients and why that variability is still not fully understood.

Dr. Mitchell and Dr. Lustig compare gene therapy to cochlear implantation, examining the practical differences in sound quality, hardware management, and the speech and language development windows that make early intervention critical regardless of which approach is used. They also address hearing screening practices, the limits of otoacoustic emissions testing in otoferlin-related cases, and what might be on the horizon for more common forms of hearing loss, including age-related degeneration and noise-induced damage.

Contact Dr. Mitchell:

Email: care@mitchellmedicalgroup.com

Website

Instagram

YouTube

Facebook

LinkedIn

Order your copy of Dr. Mitchell’s latest book, Conquering Candida, here.

Be sure to visit ImmunoLytics & use coupon code SmartestDoc for 5% off